Evaluation of recombinant tissue plasminogen activator utilization in acute ischemic stroke
- At: 2004 FIP Congress in New Orleans (USA)
- Type: Poster
- By: CHUNG, Hsiu-Li (Shin Kong WHS memorial hospital, department of pharmacy, Taipei, China Taiwan)
- Co-author(s): Wang (Shin Kong WHS memorial hospital, TAIPEI, China Taiwan)
Aims: Recombinant tissue plasminogen activator (rtPA) was approved for reducing mortality after acute ischemic stroke. In our hospital, the rtPA treatment guideline was established by department of neurology in 1997, based on guidelines from AHA Stroke Council. To ascertain the rtPA utilization and improve the quality of drug safety, we conducted.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.